---
schema_version: "secwatch.filing_event.v1"
accession: "0001493152-22-027728"
form_type: "8-K"
ticker: "SIGY"
cik: "0001642159"
company_name: "Sigyn Therapeutics, Inc."
filed_at: "2022-10-05T23:59:59+00:00"
generated_at: "2026-06-23T05:22:46.792698+00:00"
event_type: "leadership"
sentiment: "neutral"
materiality_score: 0.5
calibrated_materiality_score: 0.5
confidence: "high"
source: SEC EDGAR
---

# Sigyn Therapeutics appoints Jim Dorst, Richa Nand, and Christopher Wetzel to Board

## Summary
- Appointments effective October 10, 2022; each director brings distinct expertise.
- Jim Dorst: 30+ years finance/operations; former Director of Corporate Development at SYNNEX/Concentrix and CFO of Aethlon Medical.
- Richa Nand: IP attorney and founder of Insight Patents; biomedical researcher background at Cedars Sinai.
- Christopher Wetzel: CEO of Surgery Center at Hamilton since 2004; long-term investor in extracorporeal therapy.
- Board cited each director's experience in financial expertise, IP, or healthcare delivery as qualification.

## SEC filing metadata
- accession: 0001493152-22-027728
- form_type: 8-K
- ticker: SIGY
- cik: 0001642159
- company_name: Sigyn Therapeutics, Inc.
- filed_at: 2022-10-05T23:59:59+00:00
- event_type: leadership
- sentiment: neutral
- materiality_score: 0.5
- calibrated_materiality_score: 0.5
- confidence: high
- sec_items: 5.02
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1642159/000149315222027728/0001493152-22-027728-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1642159/000149315222027728/form8-k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001493152-22-027728
- JSON: https://secwatch.observer/filing/0001493152-22-027728.json
- Plain text: https://secwatch.observer/filing/0001493152-22-027728.txt

## Key facts
- Executive change
  Jim Dorst was appointed as Director at Sigyn Therapeutics, Inc..
  - Action: appointed
  - Role: Director
  source text: The Board of Directors of Sigyn Therapeutics, Inc. (“the Company”) appointed Jim Dorst, Richa Nand, and Christopher Wetzel to the Company’s Board of Directors effective as of October 10, 2022.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1642159/000149315222027728/0001493152-22-027728-index.htm
- Executive change
  Christopher Wetzel was appointed as Director at Sigyn Therapeutics, Inc..
  - Action: appointed
  - Role: Director
  source text: The Board of Directors of Sigyn Therapeutics, Inc. (“the Company”) appointed Jim Dorst, Richa Nand, and Christopher Wetzel to the Company’s Board of Directors effective as of October 10, 2022.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1642159/000149315222027728/0001493152-22-027728-index.htm
- Executive change
  Richa Nand was appointed as Director at Sigyn Therapeutics, Inc..
  - Action: appointed
  - Role: Director
  source text: The Board of Directors of Sigyn Therapeutics, Inc. (“the Company”) appointed Jim Dorst, Richa Nand, and Christopher Wetzel to the Company’s Board of Directors effective as of October 10, 2022.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1642159/000149315222027728/0001493152-22-027728-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.